Content status: 24 August 2026Website 2.2.2
FOR INSTITUTIONAL REVIEW

Potential value depends on the organisation – not on a universal sales promise.

A broker will review different questions from a trading desk, hedge fund or asset manager. The Framework is therefore not presented as a single-purpose product. The relevant question is: which layer matters to a specific organisation, how can it be tested in isolation, and what evidence would be required before a technical or strategic decision is made?

modular reviewdeterministic core logicstaged disclosure
FOR INSTITUTIONS

A professional reviewer needs two answers: where might strategic value reside, and how should it then be tested?

The institutional layer separates potential use cases from due diligence. Brokers, banks, trading desks, funds and FinTech providers may find different modules relevant; none of those possible roles is presented as a universal fit.

POTENTIAL FIT

Five institution types – five different review perspectives

The following describes possible points of relevance, not promised suitability. Whether a module has strategic or economic value must be assessed by the prospective organisation against its infrastructure, mandate and own review standards.

01

Broker & platform provider

Possible role

Explainable research, decision-support or rule-based analytics components embedded within an existing platform.

Typical review

Explainability, user boundaries, compliance, data rights, interfaces and technical integration.

02

Bank & trading desk

Possible role

Deterministic decision and risk components whose rules, data states and state transitions can be documented and audited.

Typical review

Model risk, auditability, security, data provenance, governance and integration into existing control processes.

03

Hedge fund & prop desk

Possible role

An additional research, decision or risk overlay if incremental value can be demonstrated under independent conditions.

Typical review

Out-of-sample behaviour, correlation, degradation, turnover, capacity, costs and robustness across regimes.

04

Asset manager & family office

Possible role

Tactical decision or risk governance, provided it is compatible with mandate, investment process and risk framework.

Typical review

Transparency, drawdown behaviour, governance, traceability and organisational fit.

05

Quant & FinTech provider

Possible role

Modular research, testing and validation components plus documented rules that could form part of a broader technology architecture.

Typical review

API boundaries, data contracts, testability, maintainability, IP rights and separation of core and optional modules.

WHERE TRANSFERABLE VALUE MAY RESIDE

Not in a single pivot or oscillator, but in the chain that has already been built.

A single indicator or formula would not be a credible build-versus-buy argument. Potential strategic value emerges only where existing research, decision rules, risk governance, test logic and documentation can jointly reduce time and research risk.

01

Historical research base

A 2009–2025 data window, 94 real instruments, 60 oscillators and a broad test matrix provide an existing starting point for further review – not a substitute for it.

02

Decision Core

Rule-based decision logic can be treated as its own layer, reproduced and later implemented independently of a particular interface or infrastructure.

03

APS Risk Layer

A separately developed risk-governance layer with stages, high-watermark protection, warning states, de-escalation and controlled restart sits above the signal logic.

04

Evidence & documentation system

Data state, rules, test conditions, limitations and version history are intended to stay attached to results so that a finding can be traced rather than merely displayed.

05

Transferable domain knowledge

Founder knowledge is institutionally useful only when it is converted from tacit knowledge into rules, documents, tests and handover processes. Productisation is designed around that requirement.

06

Modular reuse

A prospective partner does not need to adopt the entire target architecture unchanged. Value may sit in individual layers, provided dependencies and rights are clearly separated.

Deliberately conservative: these are not valuation or acquisition promises. They describe where a prospective institution may investigate strategic value. Actual value depends on revalidation, technical review, rights clearance and the specific use case.
OPERATING SUBSTANCE

A later acquirer should be able to review more than software: a traceable chain of system, real use and operating processes.

After technical revalidation, a professional trading and research office is therefore planned as an additional validation layer. An approved system version is intended to be used under real market conditions while version, decision, order, execution, risk and outcome remain connected.

07

Live track record

Real orders and fills can add an operating evidence layer to backtests, provided the traded system version is unambiguous.

08

Operating processes

Reporting, version control, risk monitoring and data management create transferable operating substance beyond source code.

09

Strategic optionality

The unit can be prepared for complete acquisition without becoming economically dependent on a single potential buyer.

Preferred target state: Where strategic fit exists, complete acquisition of the built operating unit should be possible. If no suitable transaction emerges, own operation, institutional licensing or a separate retail product can later become alternative commercialisation paths. These alternatives are not equal-priority development programmes today.

Operating validation and strategic paths in detail →

BUILD VS. BUY

The question is not whether individual components could be rebuilt.

Pivots, oscillators, databases or individual risk formulas can of course be developed again. The relevant comparison is the effort required to recreate a comparable research, testing, risk and documentation base, then validate it and integrate it into an organisation's own governance.

A prospective acquirer or partner should therefore not ask only, “Can this be coded?” but “What verified groundwork are we taking over, what risks remain open, and is the difference versus internal development strategically relevant to us?”

The appropriate benchmark

Existing substance may reduce development time and search risk. It does not replace the buyer's own due diligence or evidence that the approach adds value within the buyer's infrastructure and mandate.

FIT CHECK

Seven questions before a deeper discussion is useful

A qualified dialogue should not begin with a product demo. It should begin with whether the architecture is relevant to the organisation's requirements.

01

Is explainable, rule-based logic more suitable for the intended use than an opaque black box?

02

Should a decision or risk layer be modularly integrable into existing infrastructure?

03

Is there willingness to re-test historical findings under independently or jointly defined conditions?

04

Is separation of Decision Core, execution and risk governance relevant to model risk or internal controls?

05

Can the organisation specify requirements for data, costs, latency, capacity and compliance?

06

Is a staged review acceptable, with sensitive core IP disclosed only when justified by the review purpose?

07

Is there a real strategic use case against which build, buy or partnership can be compared?

INSTITUTIONAL FACT SHEET

One page for initial internal circulation.

The Fact Sheet summarises the architecture, documented research state, potential institutional relevance and review path on a single A4 page. It complements the more detailed Executive Overview rather than replacing it.

PDF · 1 pageEnglish & German19 August 2026
NEXT STEP

If the strategic fit is plausible, the next step is not a sales pitch – it is a structured review.

The public layer provides enough material to assess relevance. The review question is then narrowed before confidential documents or sensitive core substance are disclosed.